Therapeutics
Physostigmine Salicylate
Quick Links
Overview
Name: Physostigmine Salicylate
Synonyms: Synapton
Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Forest Laboratories, Inc.
Background
Physostigmine salicylate is a reversible acetylcholinesterase inhibitor that effectively increases the concentration of acetylcholine and thus the stimulation of both nicotinic and muscarinic receptors due to the increase in available acetylcholine at the synapse.
Last Updated: 12 Dec 2013
References
No Available References
Further Reading
No Available Further Reading
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.